Evidence of peptide vaccines eliciting anti-tumor responses in GBM and NSCLC suggests the potential for the development of robust vaccines for other EGFR-mutant cancers, including LUAD, GBM, CRAD, and HNSCC. Here, EGFR is linked to head and neck squamous cell carcinoma.